Department of Gastroenterology, Northern Jiangsu People's Hospital, Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu, China;Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China.
Turk J Gastroenterol. 2021 Jan;32(1):76-81. doi: 10.5152/tjg.2020.19566.
C-C motif ligand 5 (CCL5) is reported to play a key role in acute and chronic liver diseases. However, the association between CCL5 and chronic hepatitis B (CHB) remains to be explored. We aimed to investigate the CCL5 expression in the liver tissues of CHB patients and compared the CCL5 expression among CHB patients with different stages of liver inflammation and fibrosis.
Liver tissue specimens from 51 CHB patients who underwent liver biopsy and twelve healthy liver donors were included in the present study. CCL5 expression in the liver tissues was analyzed using immunohistochemistry. The hepatic inflammation grades and fibrotic stages of CHB patients were assessed by the Scheuer classification system.
Livers of CHB patients exhibited significantly accumulated CCL5+ cells when compared to those of healthy controls (42.80 ± 4.37 vs. 7.25 ± 0.99/HPF, P < .001). CHB patients with higher hepatic inflammation grades had more CCL5+ cells in their livers than those with lower grades (P < .05). However, the numbers of CCL5+ cells were not correlated with the fibrotic stages in CHB patients (r = .073, P = .61). The number of CCL5+ cells in the liver tissues of CHB patients was positively correlated with alanine transaminase levels (r = .278, P = .041) and aspartate aminotransferase levels (r = .328, P = .009).
CHB patients have a significant accumulation of CCL5+ cells in the liver, and CCL5 may play a pathological role in hepatic inflammation of CHB.
C-C 基序趋化因子配体 5（CCL5）被报道在急性和慢性肝病中发挥关键作用。然而，CCL5 与慢性乙型肝炎（CHB）之间的关联仍有待探讨。我们旨在研究 CHB 患者肝组织中的 CCL5 表达，并比较不同肝炎症和纤维化阶段的 CHB 患者的 CCL5 表达。
本研究纳入了 51 例接受肝活检的 CHB 患者和 12 名健康肝供体的肝组织标本。采用免疫组织化学法分析肝组织中 CCL5 的表达。采用 Scheuer 分类系统评估 CHB 患者的肝炎症分级和纤维化分期。
与健康对照组相比，CHB 患者肝脏中 CCL5+细胞明显积聚（42.80±4.37 比 7.25±0.99/HPF，P<0.001）。肝炎症分级较高的 CHB 患者肝脏中 CCL5+细胞较分级较低的患者更多（P<0.05）。然而，CHB 患者的 CCL5+细胞数量与纤维化分期无关（r=0.073，P=0.61）。CHB 患者肝组织中 CCL5+细胞数量与丙氨酸转氨酶水平（r=0.278，P=0.041）和天冬氨酸转氨酶水平（r=0.328，P=0.009）呈正相关。
CHB 患者肝脏中 CCL5+细胞明显积聚，CCL5 可能在 CHB 的肝炎症中发挥病理作用。
